Concordance and robustness of quality indicator sets for hospitals: an analysis of routine data

por Stausberg, Jürgen, Halim, Axel, Färber, Robert
Publicado 2011

Real-World Evidence of Clinical Outcomes in Patients With Assumed Classic Congenital Adrenal Hyperplasia in the United States

por Farrar, Mallory, Farber, Robert, Sen, Ginny P, Yonan, Charles, Chan, Jean Lin
Publicado 2021

MON-183 Adrenal Androgen Control and Steroidal Side Effects in Adolescents and Adults with Congenital Adrenal Hyperplasia Treated with Glucocorticoids

por Falhammar, Henrik, Farber, Robert, Chan, Jean L, Farrar, Mallory, Yonan, Chuck, Kuranz, Seth, Auchus, Richard J
Publicado 2020

OR25-03 The Effects of Crinecerfont (NBI-74788), a Novel CRF1 Receptor Antagonist, on Adrenal Androgens and Precursors in Patients with Classic Congenital Adrenal Hyperplasia: Resu...

por Auchus, Richard J, Sarafoglou, Kyriakie, Fechner, Patricia Y, Vogiatzi, Maria, Giri, Nagdeep, Roberts, Eiry, Sturgeon, Julia, Farber, Robert
Publicado 2020

Pharmacokinetics of Budesonide Oral Suspension in Children and Adolescents With Eosinophilic Esophagitis

por Gupta, Sandeep K., Hill, Malcolm, Vitanza, Joanne M., Farber, Robert H., Desai, Nirav K., Williams, James, Song, Ivy H.
Publicado 2022

OR18-4 Crinecerfont (NBI-74788), a Novel CRF1 Receptor Antagonist, Lowers Adrenal Androgens and Precursors in Adolescents with Classic Congenital Adrenal Hyperplasia

por Auchus, Richard, Chan, Jean, Farber, Robert, Fechner, Patricia, Giri, Nagdeep, Nokoff, Natalie, Roberts, Eiry, Sarafoglou, Kyriakie, Sturgeon, Julia, Vogiatzi, Maria, Newfield, Ron
Publicado 2022

TAF-4 is required for the life extension of isp-1, clk-1 and tpk-1 Mit mutants

por Khan, Maruf H., Ligon, Melissa, Hussey, Lauren R., Hufnal, Bryce, Farber, Robert, Munkácsy, Erin, Rodriguez, Amanda, Dillow, Andy, Kahlig, Erynn, Rea, Shane L.
Publicado 2013

Changes in Adrenal and Gonadal Androgens After 14-Day Treatment With CRF1 Receptor Antagonist, Crinecerfont (NBI-74788), in Men With Classic 21-Hydroxylase Deficiency

por He, Xin, Sarafoglou, Kyriakie, Fechner, Patricia Y, Vogiatzi, Maria George, Imel, Erik Allen, Davis, Shanlee Marie, Sturgeon, Julia, Chan, Jean Lin, Farber, Robert, Auchus, Richard Joseph
Publicado 2021

Growth-Related Characteristics of Patients <18 Years of Age with Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency (21OHD): Real World Evidence from the I-CAH Registr...

por Farrar, Mallory, Ali, Salma Rashid, Bryce, Jillian, Baronio, Federico, Claahsen-van der Grinten, Hedi L, Bonfig, Walter, Yonan, Charles, Farber, Robert, Chan, Jean Lin, Ahmed, S Faisal
Publicado 2021

Crinecerfont Lowers Elevated Hormone Markers in Adults With 21-Hydroxylase Deficiency Congenital Adrenal Hyperplasia

por Auchus, Richard J, Sarafoglou, Kyriakie, Fechner, Patricia Y, Vogiatzi, Maria G, Imel, Erik A, Davis, Shanlee M, Giri, Nagdeep, Sturgeon, Julia, Roberts, Eiry, Chan, Jean L, Farber, Robert H
Publicado 2021

Crinecerfont, a CRF(1) Receptor Antagonist, Lowers Adrenal Androgens in Adolescents With Congenital Adrenal Hyperplasia

por Newfield, Ron S, Sarafoglou, Kyriakie, Fechner, Patricia Y, Nokoff, Natalie J, Auchus, Richard J, Vogiatzi, Maria G, Jeha, George S, Giri, Nagdeep, Roberts, Eiry, Sturgeon, Julia, Chan, Jean L, Farber, Robert H
Publicado 2023